Reuters logo
a month ago
BRIEF-Bioinvent and ThromboGenics amending long-standing monoclonal antibody development agreement
July 10, 2017 / 5:50 AM / a month ago

BRIEF-Bioinvent and ThromboGenics amending long-standing monoclonal antibody development agreement

July 10 (Reuters) - Thrombogenics Nv:

* Bioinvent and ThromboGenics amending long-standing monoclonal antibody development agreement

* ThromboGenics nv says ThromboGenics will continue to carry all costs for development of thr-317 in non-oncology indications

* ThromboGenics nv says will be executing definitive amended agreements by q3 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below